Accera discovers and develops breakthroughs in treating central nervous system disorders, focusing on serious and difficult-to-diagnose neurodegenerative diseases for which there are no simple tests, no cures, and a lack of new, innovative therapies to improve quality of life for patients and their families. The company is pioneering unique scientific approaches to treating CNS disorders, through products with novel mechanisms of action that target the underlying factors giving rise to symptoms.
Through our proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. Based on our proprietary platform, our first product for Alzheimer's, Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
As an industry innovator, Accera's new and novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments, and their families. We are committed to improving the care and quality of life of patients.